Guideline-based indicators for adult patients with myelodysplastic syndromes.
暂无分享,去创建一个
D. Schwappach | D. Steensma | P. Fenaux | J. Passweg | J. Bohlius | M. Pfeilstöcker | U. Germing | A. Symeonidis | E. Hellstrôm-Lindberg | L. Malcovati | M. Haschke | Kristina Stojkov | T. Silzle | G. Stussi | J. Bernhard | D. Bowen | J. Čermák | A. Dinmohamed | C. Eeltink | Sabrina Eggmann | M. Heger | A. A. van de Loosdrecht | U. Platzbecker | A. M. de Almeida | M. Mittelman | Christine Morgenthaler | V. Santini | R. Stauder | S. Schär | C. Maddox | T. D. de Witte | N. Bonadies | E. Hellstrom-Lindberg
[1] U. Siebert,et al. Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group , 2020, British journal of haematology.
[2] M. Cazzola,et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. , 2020, The New England journal of medicine.
[3] U. Germing,et al. Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre , 2019, Blood.
[4] F. Thol,et al. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? , 2019, Blood advances.
[5] E. Such,et al. Do next-generation sequencing results drive diagnostic and therapeutic decisions in MDS? , 2019, Blood advances.
[6] Paul A. Harris,et al. The REDCap consortium: Building an international community of software platform partners , 2019, J. Biomed. Informatics.
[7] R. Hays,et al. The challenge of determining appropriate care in the era of patient-centered care and rising health care costs , 2018, Journal of health services research & policy.
[8] E. Ejerblad,et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population‐based setting: a report from the Swedish MDS register , 2018, British journal of haematology.
[9] P. Sonneveld,et al. MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. , 2017, Cancer epidemiology.
[10] A. Ganser,et al. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. , 2017, Blood.
[11] V. Arndt,et al. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. , 2017, Cancer epidemiology.
[12] Yin Xu,et al. CD5-Negative Mantle Cell Leukemia Shows Frequent 17p Deletion and Marrow Involvement Mimicking Marginal Zone Lymphoma , 2016 .
[13] G. Abel,et al. Assessing Quality of Care for the Myelodysplastic Syndromes , 2016, Current Hematologic Malignancy Reports.
[14] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[15] H. Uno,et al. Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes , 2016, British journal of haematology.
[16] A. Chiang. Why the Quality Oncology Practice Initiative Matters: It's Not Just About Cost. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[17] L. Godley,et al. How I diagnose and manage individuals at risk for inherited myeloid malignancies. , 2016, Blood.
[18] C. Cogle,et al. Incidence and Burden of the Myelodysplastic Syndromes , 2015, Current Hematologic Malignancy Reports.
[19] C. Kowalski,et al. Reporting program for cancer care quality indicators. , 2015, Journal of oncology practice.
[20] P. Sonneveld,et al. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. , 2015, Leukemia research.
[21] D. Neuberg,et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Buske,et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] P. Campbell,et al. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. , 2014, Blood.
[24] P. Vyas,et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes , 2014, British journal of haematology.
[25] P. Shekelle. Quality indicators and performance measures: methods for development need more standardization. , 2013, Journal of clinical epidemiology.
[26] U. Germing,et al. The impact of age on the diagnosis and therapy of myelodysplastic syndromes: results from a retrospective multicenter analysis in Germany , 2013, European journal of haematology.
[27] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[28] Ronald B. Moore,et al. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. , 2013, Journal of oncology practice.
[29] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[30] M. Scherer,et al. Methods for the guideline-based development of quality indicators--a systematic review , 2012, Implementation Science.
[31] D. Neuberg,et al. Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.
[32] O. Sibony,et al. Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review , 2011, PloS one.
[33] P. Greenberg. Myelodysplastic syndromes: dissecting the heterogeneity. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Raemaekers,et al. Development and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Porter,et al. What is value in health care? , 2010, The New England journal of medicine.
[36] C. Ko,et al. National assessment of melanoma care using formally developed quality indicators. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Westert,et al. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review , 2009, Quality and Safety in Health Care.
[38] M. Cazzola,et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Sorror,et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.
[40] Benjamin A Spencer,et al. Quality-of-care indicators for early-stage prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Hutchinson,et al. Research methods used in developing and applying quality indicators in primary care , 2003, BMJ : British Medical Journal.
[42] I. Dybedal,et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life , 2003, British journal of haematology.
[43] Robert M Califf,et al. Integrating quality into the cycle of therapeutic development. , 2002, Journal of the American College of Cardiology.
[44] A. Hutchinson,et al. Research methods used in developing and applying quality indicators in primary care , 2002, BMJ : British Medical Journal.
[45] P. Shekelle,et al. Clinical guidelines: developing guidelines. , 1999, BMJ.
[46] Andrew D Oxman,et al. Closing the gap between research and practice : an overview of systematic reviews of interventions to promote the implementation of research findings , 2011 .
[47] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[48] M. Lawrence,et al. Indicators of Quality in Health Care , 1997 .
[49] Ketelaars Ca. Using the RUMBA requirements in developing criteria. , 1994 .
[50] C. Ketelaars. Using the RUMBA requirements in developing criteria. , 1994, Nursing quality connection.
[51] J. Grimshaw,et al. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations , 1993, The Lancet.
[52] R. Lasker,et al. Containing costs while improving quality of care: the role of profiling and practice guidelines. , 1993, Annual review of public health.